Slide 1: 2nd Quarter 2026 Earnings Presentation
2nd Quarter 2026 Earnings Presentation August 10, 2026
Slide 2: Cautionary Statements
Cautionary Statements Forward-Looking Statements Statements contained in this presentation, other than statements of historical fact, are forward-looking statements. These statements can be identified by the use of words such as “believes,” “anticipates,” “expects,” “intends,” “plans,” “continues,”
Slide 3: Second Quarter 2026 Highlights
Second Quarter 2026 Highlights ~168k Consolidated Surgical Cases ~168k $848.9m 0.3% Same-Facility Growth Surgical Cases Net Revenue $849m Net Revenue 2.7% Y/Y Growth 5.0% Same-Facility Growth $125.2m Same-Facility Adjusted 5.0% Net Revenue ~190 New Physician Recruits 0.3% Surgical Cases EBITDA 4.8%
Slide 4: June 2026 YTD Highlights
June 2026 YTD Highlights ~326k Consolidated Surgical Cases ~326k $1,659.8m 0.8% Same-Facility Growth Surgical Cases Net Revenue $1,659.8m Net Revenue 3.6% Y/Y Growth 4.9% Same-Facility Growth $227.5m Same-Facility Adjusted 4.9% Net Revenue ~330 New Physician Recruits 0.8% Surgical Cases EBITDA 4.0%
Slide 5: 2026 Financial Outlook
2026 Financial Outlook The Company Reaffirms its 2026 Full Year Guidance ¹ Revenue $3.35b - $3.45b Adjusted EBITDA $530m+ Organic Adjusted EBITDA Growth 4.2%+ Same-Facility Revenue Growth 3.0%+ Third Quarter 2026 Revenue Third Quarter 2026 Adjusted EBITDA 25.0% to 25.5% of mid-point of 25.75% to 26.
Slide 6: 2026 Adjusted EBITDA Outlook Bridge from 2025
2026 Adjusted EBITDA Outlook Bridge from 2025 Proforma Adjusted EBITDA $ in millions Excluding Idaho Guidance Falls Market 2025 Adjusted EBITDA $ 526.2 $ 406 Annualize 2025 Acquisitions & Divestitures 9 9 Funding Annual Cash Incentive at Target (15) (15) 2025 Normalized Performance $ 520 $ 400 Provi
Slide 7: Idaho Falls Market Key Metrics & Business Mix Impacts
Idaho Falls Market Key Metrics & Business Mix Impacts ¹ $765m $116m Medicaid Payor Mix reduced by 50% - new 2026 Projected 2026 Projected annualized mix will be under 2% of revenue Revenue Adjusted EBITDA Eliminates Obstetrics, Neonatology, Inpatient Pediatrics and Retail & Compounding Pharmacy Serv
Slide 8: Supplemental Non-GAAP Reconciliations
Supplemental Non-GAAP Reconciliations
Slide 9: Supplemental Non-GAAP Disclosures
Supplemental Non-GAAP Disclosures Pa ge 9 | SU RG E RY PARTNE RS We are not able to project components of 2026 Adjusted EBITDA outlook.